NASDAQ:AKLI
Akili, Inc. Stock News
$0.421
+0.0007 (+0.167%)
At Close: May 31, 2024
Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds
08:00am, Thursday, 12'th Oct 2023
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.
Akili Announces Leadership Transition
07:00am, Friday, 06'th Oct 2023
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appoint
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD
08:00am, Thursday, 21'st Sep 2023
BOSTON--(BUSINESS WIRE)--Akili Releases EndeavorOTC on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD.
Akili Announces Business Transformation, Focusing on Non-prescription Model
08:00am, Wednesday, 13'th Sep 2023
BOSTON--(BUSINESS WIRE)--Akili plans transition to non-Rx business, increasing patient access to clinically-proven non-drug treatments and reducing reliance on intermediaries.
Akili, Inc. (AKLI) Q2 2023 Earnings Call Transcript
09:27am, Sunday, 13'th Aug 2023
Akili, Inc. (NASDAQ:AKLI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President, Communications Eddie Martucci - Chief Executive Offic
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
04:01pm, Thursday, 10'th Aug 2023
BOSTON--(BUSINESS WIRE)--Akili Reports Second Quarter 2023 Financial Results and Provides Business Update.
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET
07:00am, Monday, 10'th Jul 2023
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili To Presents Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at Upcoming Scientific Meetings.
Why Is Akili (AKLI) Stock Up 21% Today?
10:50am, Wednesday, 03'rd May 2023
Akili (NASDAQ: AKLI ) stock is gaining on Wednesday after the company's video game treatment showed success in reducing ADHD in adults. Akili's EndeavorRx treatment uses video games to treat patients
Akili, Inc. (AKLI) Q4 2022 Earnings Call Transcript
03:36pm, Friday, 10'th Mar 2023
Akili, Inc. (NASDAQ:AKLI ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President of Communications Eddie Martucci - Co-Founder, CEO & Dir
5 Hot Penny Stocks Exploding After News This Week
09:39am, Thursday, 05'th Jan 2023
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Akili, Inc. (AKLI) Q3 2022 Earnings Call Transcript
04:25am, Sunday, 13'th Nov 2022
Akili, Inc. (NASDAQ:AKLI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Joshua Young - IR Walter Martucci - Co-Founder, CEO & Director Matthew Franklin - Presiden
Akili: Developing Video Games To Treat Cognitive Impairments
05:52pm, Monday, 31'st Oct 2022
Akili is developing video games as a means to treat ADHD, depression, and other conditions. The company has approval by the FDA to treat ADHD using its product EndeavorRx. It is also approved to marke
Akili Completes Business Combination With Social Capital Suvretta Holdings Corp. I (DNAA)
06:54am, Saturday, 20'th Aug 2022
Akili announced it has completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I (DNAA). These are the details.
Akili to Present at Cowen's 42nd Annual Health Care Conference
07:00am, Monday, 07'th Mar 2022
BOSTON--(BUSINESS WIRE)-- #DTx--Akili Management to Present at Cowen's 42nd Annual Health Care Conference
